<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="200546">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479453</url>
  </required_header>
  <id_info>
    <org_study_id>8299</org_study_id>
    <secondary_id>F1J-MC-HMCX</secondary_id>
    <nct_id>NCT00479453</nct_id>
  </id_info>
  <brief_title>Lilly's Emotional and Physical Symptoms of Depression</brief_title>
  <acronym>LEAPS</acronym>
  <official_title>Lilly's Emotional and Physical Symptoms of Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effectiveness of duloxetine administered once daily in patients with Major
      Depressive Disorder in a practice based setting
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess physical and emotional symptoms of depressed patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression of Severity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Somatic Symptom Inventory</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Depressive Symptomatology-Self Report</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood and Physical Symptoms in Depression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Enjoyment and Satisfaction Questionnaire - Short form</measure>
  </secondary_outcome>
  <enrollment>8000</enrollment>
  <condition>Major Depressive Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>duloxetine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet criteria for major depressive disorder according to the DSM-IV diagnostic
             criteria

          -  Outpatients at lease 18 years of age

          -  Sign the informed consent

          -  All females must test negative for a urine pregnancy test at visit 1. Females of
             child bearing potential must agree to utilize medically acceptable and reliable means
             of birth control

          -  Have a level of understanding sufficient to communicate with the investigator and are
             able to complete all patient self-rated scales in the study

        Exclusion Criteria:

          -  Are investigator site personnel directly affiliated with the study or immediate
             family

          -  Are employed by Eli Lilly and Company

          -  Have received treatment within the last 30 days or are currently enrolled in a study
             with a drug that has not received regulatory approval for any indication at time of
             study entry

          -  Current substance dependence, excluding nicotine and caffeine

          -  Treatment with a monoamine oxidase inhibitor within 14 days prior to visit 1 or
             potential need to use an MAOI within 5 days after discontinuation of study drug

          -  Acute liver injury or severe (Child-Pugh Class C) cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manati</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>May 2007</verification_date>
  <lastchanged_date>May 25, 2007</lastchanged_date>
  <firstreceived_date>May 25, 2007</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
